Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Abbreviations AA: Amino acid [Ca 2+ ] i : Cytoplasmic free Ca 2+ concentration DPP-4: Dipeptidyl peptidase 4 EGFP: Enhanced green fluorescent protein GCGR: Glucagon receptor GLP-1: Glucagon-like peptide 1 GLP-1R: GLP-1 receptor GPCR: G protein-coupled receptor GRA: Glucagon receptor antagonist IC 50 : Half-maximal inhibitory concentration NPY: Neuropeptide Y PKA: Protein kinase A PPPG: Preproglucagon promoter P/Q-type Ca 2+ channel: Voltage-gated Ca 2+ channel sensitive to -agatoxin PTX: Pertussis toxin TIRF (microscopy): Total internal reflection fluorescence (microscopy) VGCC: Voltage-gated calcium channel References Cryer PE (2015) Hypoglycemia-associated autonomic failure in diabetes: maladaptive, adaptive, or both
Clinical Evidence for Dual-Peptide Weight Loss Therapy Published data on GLP-1 monotherapy shows average weight loss of 1522% over 68 weeks in phase 3 trials, with sustained improvements in waist circumference and cardiometabolic markers
Expected Timeline of Results Weeks 1 to 2: Appetite reduction from semaglutide begins Weeks 2 to 4: GHK-Cu initiated
15 IGF1R-deficient mice showed organ hypoplasia, delayed skeletal calcification, severe growth retardation, and invariably died postnatally as a result of respiratory dysfunction
